Nancy Bartlett, MD, Oncology, Saint Louis, MO, Siteman Cancer Center

NancyLeeBartlettMD

Oncology Saint Louis, MO

Hematologic Oncology

Professor, Internal Medicine, Washington University School of Medicine

Overview of Dr. Bartlett

Dr. Nancy Bartlett is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Siteman Cancer Center, Barnes-Jewish Hospital, and Barnes-Jewish West County Hospital. She received her medical degree from Washington University School of Medicine in St. Louis and has been in practice 31 years. Dr. Bartlett accepts several types of health insurance, listed below. She is one of 102 doctors at Barnes-Jewish Hospital and one of 41 doctors at Barnes-Jewish West County Hospital who specialize in Oncology.

Education & Training

  • Stanford University
    Stanford UniversityFellowship, Medical Oncology, 1990 - 1993
  • UCSF
    UCSFInternship, Internal Medicine, 1986 - 1987
  • Washington University School of Medicine in St. Louis
    Washington University School of Medicine in St. LouisClass of 1986

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 1993 - 2022
  • CA State Medical License
    CA State Medical License 1988 - Present
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma  
    Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
  • Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study  
    Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
  • Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma  
    Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine
  • Join now to see all

Abstracts/Posters

  • North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
    Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
    Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as...
    Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Cancer Clinical Trial Access Expands in St. Louis Area Thanks to $7.8m to Siteman Cancer Center
    Cancer Clinical Trial Access Expands in St. Louis Area Thanks to $7.8m to Siteman Cancer CenterAugust 2nd, 2019
  • Siteman Cancer Center Awarded $7.8 Million to Expand Clinical Trials Access
    Siteman Cancer Center Awarded $7.8 Million to Expand Clinical Trials AccessAugust 1st, 2019
  • Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL
    Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCLJuly 1st, 2019
  • Join now to see all

Grant Support

  • Wumc Cancer And Leukemia Group BNational Cancer Institute2009–2012
  • Data And Safety MonitoringNational Cancer Institute2010–2011
  • Wumc-Cancer And Leukemia Group BNational Cancer Institute2003–2008
  • Quality Assurance And Safety MonitoringNational Cancer Institute2004
  • 24hr Infusion Of Hmr1275 In Fludarabine--B Cell LeukemiaNational Center For Research Resources2000–2002
  • Wusm Cancer And Leukemia Group BNational Cancer Institute1998–2002
  • Coadmin Rising Oral Gg918 Dose Levels (GH120918) W/ Doxorubicin In Cancer PTSNational Center For Research Resources1998–1999

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    BCBS Massachusetts Blue Care Elect PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Coventry Health Care PPO Platinum
    Coventry Missouri - HMO/POS
    First Health PPO
    Great West PPO
    HealthLink PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment